Due to the complicated nature of and expense behind developing and manufacturing antibody drug conjugates (ADCs), around 70% of ADC developers rely on the support of contract development and manufacturing organizations (CDMOs). It is, therefore, vital to choose a CDMO that has extensive expertise in ADC development, as well as manufacturing scale up and cytotoxic fill and finish facilities to supply material for early phase clinical studies through to commercialization.
White paper highlights
This white paper explores how Lonza is revolutionizing the field of ADCs with our comprehensive end-to-end lifecycle support.
Market Growth and Innovation
With over 200 ADCs in clinical development and an estimated market value of $36 billion by 2029, innovation in ADCs is driving significant advancements in cancer therapy.
Expertise and Facilities
Our extensive experience since 2006, with state-of-the-art facilities in Visp and Basel, Switzerland, ensures efficient and scalable ADC development and manufacturing.
Bioconjugate Diversity
Learn about the diverse range of bioconjugates beyond ADCs, including polymers, oligonucleotides, and nanobodies, supported by our Bioconjugation Toolbox.